Lincomycin Syrup 250mg 5ml Oral Suspension

• Application: Internal Medicine
• Usage Mode: For oral administration
• Suitable for: Elderly, Children, Adult
• State: Syrup
• Shape: Oral Liquid
• Type: Biological Products
• Model NO.: 250mg 5ml
• Pharmaceutical Technology: Chemical Synthesis
• Transport Package: Carton
• Specification: 250mg 5ml, 1bottle/box
• Trademark: RYAN PHARMA
• Origin: China

Product Description

Lincomycin Syrup 250mg/5ml-60ml

DESCRIPTION:
Lincomycin Syrup contains lincomycin hydrochloride which is the monohydrate salt of lincomycin, a substance produced by the growth of a member of the lincolnensis group of Streptomyces lincolnensis (Fam. Streptomycetaceae). The chemical name for lincomycin hydrochloride is Methyl 6,8-dideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrolidinecarboxamido)-1-thio-D-erythro-á-D- galacto-galactopyranoside monohydrochloride monohydrate. The molecular formula of lincomycin hydrochloride is
C₁₈H₃₄N₂O₆S·HCl·H₂O and the molecular weight is 461.01.
The structural formula is represented below:


COMPOSITION AND AVAILABITY:
Lincomycin Syrup: Each 5ml (teaspoonful) contains the equivalent of 250mg lincomycin base (from lincomycin hydrochloride monohydrate).
INDICATIONS:
Lincomycin is indicated in the treatment of infections due to susceptible strains of streptococci, pneumococci, and staphylococci.
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to lincomycin.
Lincomycin (HCl) is primarily indicated in conditions like Anaerobic infections, Chronic middle ear infection, Colitis, Impetigo, Osteomyelitis, Pneumonia.
PHARMACOKINETICS:
Oral absorption of Lincomycin (HCl) is found to be 27.5%. Plasma protein binding is 72%. and metabolism is reported partially Hepatic. Renal Excretion accounts for 13% and plasma half-life is 4.4hr.
CONTRA-INDICATION:
This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.
SIDE EFFECTS:
The severe or irreversible adverse effects of Lincomycin (HCl), which give rise to further complications include Pseudomembranous colitis, Thrombocytopenia, Angioneurotic edema, Serum sickness, Granulocytopenia, Leucopenia, Neutropenia, Erythema multiforme, Glossitis, Elevated transaminases, Apnea, Erythema multiforme, Vaginitis.
Lincomycin (HCl) produces potentially life-threatening effects which include Syncope, Hypotension, Anaphylaxis. which are responsible for the discontinuation of Lincomycin (HCl) therapy.
The symptomatic adverse reactions produced by Lincomycin (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Diarrhea, Fever, Tinnitus, Skin rashes, Urticaria, Vertigo X, Stomatitis X, Esophagitis, Perianal irritation, Rectal irritation, Vaginal irritation, Skin rashes.
DRUG INTERACTIONS:
Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used in caution in patients receiving such agents.
Antagonism between lincomycin and erythromycin in vitro has been demonstrated. Because of possible clinical significance, the two drugs should not be administered concurrently.
WARNINGS /PRECAUTIONS:
Lincomycin should be used with caution in patients with kidney or liver disease. Take appropriate measures in case of secondary infections. It should be used with caution (if contains tartrazine) in patients with aspirin hypersensitivity, because it may cause allergic reactions (including bronchial asthma).
HIGH RISK GROUP:
Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, Geriatrics, and Neonates.
If prescribing authority justifies the benefits of the drug against the possible damages, he/she should reevaluate them and consult the reference material and previous studies.
OVERDOSE:
Serum levels of Lincomycin are not appreciably affected by hemodialysis and peritoneal dialysis.
DOSAGE AND ADMINISTRATION:
1-6 months: 1.25ml-2.5ml three times daily.
6 months to 2 years: 2.5ml-5ml three times daily.
3-9 years: 2.5-5ml four times daily.
10-12 years: 5-10ml four times daily.
Neonates under one month not recommended.
PATIENTS WITH DIMINISHED RENAL FUNCTION:
When therapy with LINCOMYCIN is required in individuals with severe impairment of renal function, an appropriate dose is 25 to 30% of that recommended for patients with normally functioning kidneys.
STORAGE:
Store below 30ºC in a dry place. Protect from heat & light.
Keep all medicines out of the reach of children.
To be sold on the prescription of a registered medical practitioner only.
PACKING:
A glass bottle of 60mL packed on a unit pack.
VALIDITY:
3 years.